Your browser doesn't support javascript.
loading
Symptom presentation among SARS-CoV-2 positive cases and the impact of COVID-19 vaccination; three prospective household cohorts
Ilse Westerhof; Marieke de Hoog; Margareta Ieven; Christine Lammens; Janko van Beek; Ganna Rozhnova; Dirk Eggink; Sjoerd Euser; Joanne Wildenbeest; Marlies van Houten; Herman Goossens; Carlo Giaquinto; Patricia Bruijning Verhagen.
Affiliation
  • Ilse Westerhof; Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, The Netherlands
  • Marieke de Hoog; Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, The Netherlands
  • Margareta Ieven; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
  • Christine Lammens; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
  • Janko van Beek; Department of Viroscience, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
  • Ganna Rozhnova; Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, The Netherlands and Biosystems & Integrative
  • Dirk Eggink; Centre for Infectious Disease Control, WHO COVID-19 Reference Laboratory, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Nether
  • Sjoerd Euser; Streeklaboratorium voor de Volksgezondheid Kennemerland, Department of Epidemiology, Kennemerland, The Netherlands
  • Joanne Wildenbeest; Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Childrens Hospital University Medical Center Utrecht, Utrecht, The Netherlands
  • Marlies van Houten; Spaarne Gasthuis Academy, Spaarne Gasthuis, Hoofddorp, The Netherlands and Spaarne Gasthuis, department of Pediatrics, Haarlem and Hoofddorp, The Netherlands
  • Herman Goossens; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
  • Carlo Giaquinto; Department of Women and Child Health, University of Padova, Padova, Italy
  • Patricia Bruijning Verhagen; Julius Centre for Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, The Netherlands
Preprint in English | medRxiv | ID: ppmedrxiv-22278985
ABSTRACT
OBJECTIVEUsing data from European prospective household studies, we systematically compared the symptom burden of the wild-type and Alpha variant infected individuals versus the Omicron BA.1 and BA.2 infected individuals across paediatric and adult age-groups. In addition, we measured the impact of COVID-19 vaccination on the Omicron symptom burden. METHODSThe household transmission studies were conducted during the wild-type and Alpha period (April 2020 to April 2021) and the early Omicron BA.1 and BA.2 dominant period (January to March 2022). All three studies used similar protocols. Households were prospectively followed from detection of the first SARS-CoV-2 index case until at least day 21 including (repeated) PCR testing, paired serology and daily symptom reporting for all household members. To avoid possible index-case ascertainment bias, we restricted analyses to secondary household cases. Age-stratified SARS-CoV-2 symptom burden was compared for wild-type/Alpha versus Omicron infections and for primary versus primary plus booster series vaccinated adult cases. FINDINGSIn total 216 secondary cases from wild-type/Alpha, and 130 from the Omicron period were included. Unvaccinated children <12 years experienced more symptoms and higher maximum and cumulative severity scores during the Omicron compared to the wild-type/Alpha period (p=0.004, p=0.011 and p=0.075, respectively). In adults, disease duration and maximum and cumulative severity scores were reduced during the Omicron period. Adjusted for age, gender and prior immunity Omicron was associated with lower odds for loss of smell or taste (Odds Ratio [OR] 0.14; 95%CI 0.03-0.50), and higher, but non-significant odds for upper respiratory symptoms, fever and fatigue (ORs varying between 1.85-2.23). Comparing primary versus primary plus booster vaccinated adult cases during the Omicron period no differences were observed in disease severity or duration (p[≥]0.12). INTERPRETATIONIn children, the Omicron variant causes higher symptom burden compared to the wild-type/Alpha. Adults experienced a lower symptom burden possibly due to prior vaccination. A shift in most frequently reported symptoms occurred with a marked reduction in loss of smell or taste during the Omicron period. An additional effect of booster vaccination on symptom severity in infected adults compared to primary series only, could not be demonstrated.
License
cc_no
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Experimental_studies / Observational study / Prognostic study / Rct Language: English Year: 2022 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Experimental_studies / Observational study / Prognostic study / Rct Language: English Year: 2022 Document type: Preprint
...